EUVIMEDEUVIMED entdecken
Crossref

Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy

Takanari Kambe iD, Toshinari Yamasaki, Akihiro Yamamoto, Akihiko Nagoshi, Tasuku Fujiwara, Yuta Mine, Hiroki Hagimoto iD, Atsushi Igarashi, Hidetoshi Kokubun, Shiori Murata, Naoki Akagi, Yuto Hattori iD und 4 weitere

International Journal of Urology · 2024

DOI: 10.1111/iju.15579 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2024. Verfasst von Takanari Kambe und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Estramustine, Prostatectomy, Prostatic Neoplasms, Robotic Surgical Procedures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The objective of this study is to evaluate the safety and efficacy of neoadjuvant degarelix acetate and low‐dose estramustine phosphate for high−/very high‐risk prostate cancer.

Methods

Overall, 187 patients diagnosed with National Comprehensive Cancer Network high−/very high‐risk cTanyN0M0 localized prostate cancer who consented to undergo robot‐assisted radical prostatectomy after receiving neoadjuvant chemohormonal therapy for 6 months were prospectively enrolled between December 2017 and March 2023. Adverse events, perioperative and histopathological outcomes, and biochemical recurrence‐free survival rates were examined. Survival analysis compared the estramustine phosphate completion and reduction groups.

Results

Thirty‐six patients discontinued neoadjuvant therapy in

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EstramustineProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresNeoplasm Recurrence, LocalNeoadjuvant TherapyHumansMaleAgedMiddle AgedProspective StudiesOligopeptidesProstate-Specific AntigenAntineoplastic Combined Chemotherapy ProtocolsDisease-Free Survival

Stichwörter der Autor:innen

high‐riskneoadjuvant chemohormonal therapyneoadjuvant therapyprostate cancervery high‐risk

Substanzen

Estramustineacetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(…OligopeptidesProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan.

ORCID-Profile: Takanari Kambe, Hiroki Hagimoto, Yuto Hattori

Zitieren

APA

Kambe, T., Yamasaki, T., Yamamoto, A., Nagoshi, A., Fujiwara, T., Mine, Y., Hagimoto, H., Igarashi, A., Kokubun, H., Murata, S., Akagi, N., Hattori, Y., Abe, Y., Tsutsumi, N., Shibasaki, N., & Kawakita, M. (2024). Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy. International Journal of Urology. https://doi.org/10.1111/iju.15579

Vancouver

Kambe T, Yamasaki T, Yamamoto A, Nagoshi A, Fujiwara T, Mine Y, et al. Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy. International Journal of Urology. 2024. doi:10.1111/iju.15579

BibTeX
@article{Kambe2024,
  author = {Kambe, Takanari and Yamasaki, Toshinari and Yamamoto, Akihiro and Nagoshi, Akihiko and Fujiwara, Tasuku and Mine, Yuta and Hagimoto, Hiroki and Igarashi, Atsushi and Kokubun, Hidetoshi and Murata, Shiori and Akagi, Naoki and Hattori, Yuto and Abe, Yohei and Tsutsumi, Naofumi and Shibasaki, Noboru and Kawakita, Mutsushi},
  title = {Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy},
  journal = {International Journal of Urology},
  year = {2024},
  doi = {10.1111/iju.15579}
}
Kostenlos starten →